The DreamChanger Intervention in Combination With Imagery Rehearsal Therapy for Children's Nightmares
- Disease/Condition
- Nightmare
- Drug/Device/Intervention
- DreamChanger+IRT
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Tel Aviv University
- Location
- Tel Aviv, Israel
- Phase
- N/A
- Start date
- May 01, 2024
- End date
- Dec 01, 2025
- Enrollment
- 120 participants
Nightmare frequency and severity
This clinical trial will test the efficacy of parent-delivered DreamChanger Intervention in
 combination with Imagery Rehearsal Therapy (IRT) for reducing the frequency and severity of
 nightmares in children aged 3-10. Children will be randoimized to either the combined
 intervention or to a waitlist control group.The intervention will include providing children
 with the DreamChanger remote, and providing parents with instructional videos, explaining how
 to use the device along with the IRT strategy to address nightmares.
 
 At baseline, mid-treatment, and post-treatment, parents in both groups will complete
 questionnaires asking about the child's nightmares, sleep, externalizing and internalizing
 symptoms, PTSD symptoms, demographic characteristics, and parent sleep and distress. Parents
 in the intervention group will also be asked to complete questionnaires regarding their
 compliance and satisfaction with the intervention, as well as a 3-month follow-up assessment.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06410118
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06410118 through Pure Global AI's free database. This phase not specified trial is sponsored by Tel Aviv University and is currently Not yet recruiting. The study focuses on Nightmare. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.